ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 12 of 532 for:    Recruiting, Not yet recruiting, Available Studies | "Multiple Myeloma"

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02916771
Recruitment Status : Recruiting
First Posted : September 27, 2016
Last Update Posted : November 30, 2017
Sponsor:
Collaborators:
Celgene
Takeda
Information provided by (Responsible Party):
Irene Ghobrial, MD, Dana-Farber Cancer Institute

Brief Summary:
This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.

Condition or disease Intervention/treatment Phase
Smoldering Multiple Myeloma Drug: Ixazomib Drug: Lenalidomide Drug: Dexamethasone Phase 2

Detailed Description:

This research study is a Phase II clinical trial, which tests the effectiveness of an investigational drug(s). The investigational drugs used in this research study are Ixazomib, Lenalidomide and Dexamethasone.

"Investigational" means that the FDA (the U.S. Food and Drug Administration) has not approved the combination of Ixazomib, Lenalidomide and Dexamethasone as a treatment regimen for Smoldering Multiple Myeloma. The purpose of this research study is to learn whether the combination of Ixazomib, Lenalidomide, and Dexamethasone works in treating Smoldering Multiple Myeloma.

Ixazomib is a drug that may kill or stop cancer cells from growing by blocking the proteasome within the cell, which is responsible for degrading or breaking down a variety of proteins. This type of drug is called a proteasome inhibitor. Lenalidomide is an immunomodulatory drug, meaning it modifies the participant immune system to help fight the participant disease. Dexamethasone is a steroid, which is usually combined with other drugs to enhance their effects to fight the participant disease.

Ixazomib is approved by the FDA in combination with Lenalidomide and Dexamethasone for the treatment of Multiple Myeloma and is currently being evaluated for use in the treatment of several types of cancers. Both Lenalidomide and Dexamethasone have been previously approved by the FDA for the treatment of Multiple Myeloma, as well as several other cancers.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Study Start Date : October 2016
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : April 2024


Arm Intervention/treatment
Experimental: Ixazomib
  • Cycles 1-9

    • Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle
    • Lenalidomide is administered orally on days 1-21 on a 28 days cycle
    • Dexamethasone is administered orally on days 1, 8, 15, 22 on a 28 days cycle
  • Cycle 10-24

    • Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle
    • Lenalidomide is administered orally on days 1-21 on a 28 days cycle
  • Supportive measures consistent with optimal patient care may be given throughout the study
Drug: Ixazomib
Oral, proteasome inhibitor
Other Name: Ninlaro

Drug: Lenalidomide
Oral, immunomodulatory agent
Other Name: Revlimid

Drug: Dexamethasone
Oral, steroid
Other Name: Decadron




Primary Outcome Measures :
  1. Proportion Of High Risk SMM Patients Who Are Progression Free 2 Years After Receiving IRD Combination Therapy [ Time Frame: 2 years ]
    The proportion of patients who achieve progression free at 2 years will be compared to the rate published for the high risk SMM. By the Mayo Clinic model for risk factors, the median time to progression for patients with high risk SMM was only 1.9 years. Therefore, we assume that, a 2-years progression-free rate of 50% will not be considered promising and a true progression free rate of 75% or higher will be considered promising.


Secondary Outcome Measures :
  1. Progression Free Survival [ Time Frame: Time from protocol therapy initiation to the disease progression or death from any cause, censored at date last known progression free for those who have not progressed or died, or up to 60 months post initiation of therapy ]
    Progression-free survival is defined as the time from protocol therapy initiation to the disease progression or death from any cause, censored at date last known progression free for those who have not progressed or died

  2. Time To Progression [ Time Frame: The time from protocol therapy initiation until documented progression, censored at date last known progression-free for those who have not progressed or up to 60 months post initiation of therapy ]
    Time to progression (TTP) is defined as the time from protocol therapy initiation until documented progression, censored at date last known progression-free for those who have not progressed.

  3. Duration of Response [ Time Frame: time from objective response to disease progression or death, or date last known progression-free and alive for those who have not progressed or died, or up to 60 months post initiation of therapy ]
    Duration of response is defined as the time from objective response to disease progression or death, or date last known progression-free and alive for those who have not progressed or died

  4. Objective Response Rate [ Time Frame: 2 years ]
    The objective response rate is defined as partial response or better according to the modified IMWG criteria and the proportion of patients with a MRD, CR, PR or MR will be reported with 90% exact binominal confidence interval (CI)

  5. Overall Survival [ Time Frame: Time from protocol therapy initiation to death or date last known alive, or up to 60 months post initiation of treatment ]
    Overall survival is defined as the time from protocol therapy initiation to death or date last known alive



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years.
  • Must meet criteria of high risk smoldering MM based on the criteria described below:
  • Definition of high-risk SMM:

    --Bone marrow clonal plasma cells ≥10% and ≤60% and any one or more of the following:

    • Serum M protein ≥3.0g/dL (IgA, IgG, IgM, or IgD)
    • IgA SMM
    • Immunoparesis with reduction of two uninvolved immunoglobulin isotypes
    • Serum involved/uninvolved free light chain ratio ≥8 (but less than 100)

      ----Free Light Chain Smoldering Myeloma patients as defined in section 2.4 are not excluded

    • Progressive increase in M protein level (Evolving type of SMM)

      ----Increase in serum monoclonal protein by ≥10% on two successive evaluations within a 6 month period

    • Bone marrow clonal plasma cells 50-60%
    • Abnormal plasma cell immunophenotype (≥95% of bone marrow plasma cells are clonal) and reduction of one or more uninvolved immunoglobulin isotypes
    • t (4;14) or del 17p or 1q gain
    • Increased circulating plasma cells
    • MRI with diffuse abnormalities or 1 focal lesion
    • PET-CT with one focal lesion with increased uptake without underlying osteolytic bone destruction
    • Urine monoclonal light chain excretion ≥500 mg/24 hours
  • ECOG Performance Status (PS) 0, 1, or 2 (Appendix A)
  • The following laboratory values obtained ≤ 21 days prior to registration and confirmed prior to the first dose of study drug:

    • ANC ≥ 1000/uL
    • PLT ≥ 75,000/uL. Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment.
    • Total bilirubin ≤ 1.5 mg/dL (If total is elevated check direct and if normal patient is eligible.)
    • AST ≤ 3 x institutional upper limit of normal (ULN)
    • ALT ≤ 3 x institutional upper limit of normal (ULN)
    • Calculated creatinine clearance ≥ 30 mL/min
  • Ability to understand and the willingness to sign a written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
  • Female patients who are postmenopausal for at least 1 year before the screening visit or are surgically sterile. Females of childbearing potential* must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days as required by Revlimid REMS®) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. Female patients must agree to practice two effective methods of birth control from the time of signing the informed consent form though 90 days after the last dose of study drug
  • A female of childbearing potential is a sexually mature female who:

    • Has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or
    • Has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months)
  • All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program.
  • Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program.
  • Men must agree to use a latex condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy during the entire study treatment period and through 90 days after the last dose of study drug OR agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)

Exclusion Criteria:

  • No evidence of CRAB* criteria or new criteria of active MM which including the following:

    • Increased calcium levels (corrected serum calcium >0.25 mmol/dL above the upper limit of normal or >.275 mmol/dL) related to MM
    • Renal insufficiency (attributable to MM)
    • Anemia (Hb 2g/dL below the lower limit of normal or <10g/dL) related to MM
    • Bone lesions (lytic lesions or generalized osteoporosis with compression fractures)
    • Bone marrow plasma cells ≥60%
    • Serum involved/uninvolved FLC ratio ≥100, provided the absolute level of the involved free light chain is at least 100 mg/L and repeated twice
    • MRI with two or more focal lesion that is at least 5 mm or greater in size
  • Participants with CRAB criteria that are attributable to conditions other than the disease under study may be eligible
  • Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational. Prior therapy with bisphosphonate is allowed. Prior radiation therapy to a solitary plasmacytoma is allowed.
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  • Diagnosed or treated for another malignancy within 2 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant or nursing women will be excluded from the study because lenalidomide is an agent with the potential for teratogenic or abortifacient effects.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ixazomib or lenalidomide.
  • Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.
  • Major surgery within 14 days before enrollment.
  • Known Amyloid involvement.
  • Myeloma-related central nervous system involvement.
  • Systemic treatment, within 14 days before the first dose of ixazomib with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort.
  • Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing.
  • Grade 2 peripheral neuropathy or higher or grade 1 with pain on clinical examination during the screening period.
  • Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial.
  • Previous treatment with ixazomib, or participation in a study with ixazomib whether treated with ixazomib or not.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02916771


Contacts
Contact: Alexandra Savell 617-632-3539 asavell@partners.org

Locations
United States, Massachusetts
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02115
Contact: Irene M Ghobrial, MD    617-632-4198    Irene_Ghobrial@dfci.harvard.edu   
Principal Investigator: Irene M Ghobrial, MD         
Sponsors and Collaborators
Dana-Farber Cancer Institute
Celgene
Takeda
Investigators
Principal Investigator: Irene M Ghobrial, MD Dana-Farber Cancer Institute

Responsible Party: Irene Ghobrial, MD, Irene M. Ghobrial, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT02916771     History of Changes
Other Study ID Numbers: 16-313
First Posted: September 27, 2016    Key Record Dates
Last Update Posted: November 30, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Irene Ghobrial, MD, Dana-Farber Cancer Institute:
Smoldering Multiple Myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone acetate
Dexamethasone
Lenalidomide
Ixazomib
Thalidomide
BB 1101
Glycine
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists